Gilead Sciences entered the next reporting window with broad second-quarter growth. Revenue increased 10% to $7.8 billion, while product sales excluding Veklury rose 10% to $7.6 billion. That advance places the October 29 results update at the center of the next evidence check.
The HIV franchise remained the main engine. HIV sales increased 12% to $5.7 billion, while Biktarvy rose 7% to $3.8 billion. In oncology, Trodelvy sales advanced 26% to $457 million, with the source describing that gain as demand led.
Recent regulatory progress adds breadth, not certainty. The FDA approved Bixlenvo for virologically suppressed adults with HIV, and the European Commission expanded first-line Trodelvy authorization across PD-L1 status in metastatic triple-negative breast cancer. Those decisions widen the commercial story while leaving execution and adoption to future reports.
Cash conversion remains the balancing issue. Second-quarter operating cash flow was $3.6 billion, but June cash, equivalents and marketable debt securities stood at $3.2 billion after substantial acquisition outflows, debt repayments, dividends and repurchases during the first half. The October 22 HCXT-2001 agreement adds another capital-allocation question because the asset remains in Phase 1 and closing is still subject to customary conditions.
Pipeline evidence also needs careful separation from completed approvals. The Phase 2 SWIFT study reported a 66% clinical response rate for emvistegrast 200 mg versus 37% for placebo at Week 12 using nominal p-values. Conference schedules for IDWeek and The Liver Meeting show research breadth, but previews alone do not establish clinical or commercial outcomes.
The October 29 release should clarify whether core growth, guidance quality and operating cash generation are keeping pace with a broader but more capital-intensive franchise. The full Gilead Sciences premium review provides the deeper evidence map and risk framework.
Market analysis, not personalized investment advice.